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SUMMARY
Sulfonamide derivatives are well known for their an-
tibacterial activity as manifested by ‘Sulfa Drugs’, for 
example, sulfamethoxazole etc. In addition, they are 
associated with a large number of pharmacological 
activities such as anti-microbial, anti-inflammatory, 
anti-cancer, anti-oxidant, anti-viral etc. This work 
has emphasized their application as antiviral agents 
such as HIV (human immunodeficiency virus), HCV 
(hepatitis C virus) etc. We have presented here a num-
ber of sulfonamide derivatives exhibiting remarkable 
antiviral potential.
Keywords: Sulfonamides, antiviral, anti-HIV, an-
ti-HCV.
RESUMEN
Los derivados de sulfonamida son bien conocidos 
por su actividad antibacteriana tal como se ha ma-
nifestado en  los ‘Fármacos Sulfa’, por ejemplo, el 
sulfametoxazol, etc... Además, están asociados a un 
gran número de actividades antifarmacológicas como 
la antimicrobiana, antinflamatoria, anticancerígena, 
antioxidante, antiviral, etc. Este estudio ha resaltado 
su aplicación como agentes antivirales como el HIV 
(virus de inmunodeficiencia humana), HCV (virus de 
la hepatitis C) etc. Hemos presentado aquí una serie 
de derivados de sulfonamida que exhiben un notable 
potencial antiviral.
Palabras clave: Sulfonamidas; antiviral; anti-HIV; 
anti-HCV.
RESUM
Els derivats de sulfonamida son ben coneguts per la 
seva activitat antibacteriana tal como s’ha vist en els 
‘Fàrmacs Sulfa’, per exemple, el sulfametoxazol, etc.. 
A més a més estan associats a un gran número de ac-
tivitats antifarmacològiques com la antimicrobiana, 
antiinflamatòria, anticancerígena, antioxidant, anti-
viral, etc. Aquest estudi ha ressaltat la seva aplicació 
com agents antivirals com el HIV (virus de immuno-
deficiència humana), HCV (virus de la hepatitis C) 
etc. Hem presentat aquí una sèrie de derivats de sul-
fonamida que mostren un notable potencial antiviral.
Paraules clau: Sulfonamides; antiviral; anti-HIV; 
anti-HCV.
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INTRODUCTION
Sulfonamide, a well known functionality, is asso-
ciated with a wide spectrum of biological activities. 
A large number of pharmacologically potent sulfon-
amides having potential as antimicrobial, anti-inflam-
matory, anti-viral, antioxidant and enzyme inhibitory 
have also been synthesized1-8 and well characterized 
by XRD9-43. In order to obtain compounds with en-
hanced activity against drug-resistant viruses diver-
sified sulfonamide derivatives are being further ex-
plored. No effective vaccine to cure HIV-1 is available, 
so, anti-viral drugs are the only means to cure replica-
tion and transmission of this death causing virus. Up 
till now, many sulfonamide scaffolds with anti-viral 
potential44-48 have been presented and some are also 
available in market (Fig. 1) which play their inhibitory 







































Fig. 1. Some important anti-HIV sulfonamide drugs.
HCV (Hepatitis C virus) is remarkably associated 
with chronic liver and acute hepatitis disease which 
also include liver cancer and fibrosis cirrhosis. It is es-
timated that HCV has affected 3% people world over 
while each year 3-4 million people are being infected 
chronically. Some sulfonamide scaffolds having an-
ti-HCV potential are also available in the market like 

















Fig. 2. Commercially available anti-HCV sulfonamide 
drug, Asunaprevir.
Sulfonamides as anti-HCV agents
In 2003, Johansson and co-researchers synthe-
sized novel sulfonamide derivatives which were in-
hibitors of protease and found active against HCV 
NS3 (Protease-Helicase/NTPase). Derivatives 1 and 
2 exhibited excellent potential with Ki values of 3.8 
and 13.6 nM respectively49. Similarly, among the 
synthesized sulfonamide derivatives by Yannopou-
los and co-workers, the derivative 3 demonstrated 
remarkable inhibition against HCV (NS5B poly-
merase) with an IC50 value of 25 µM50. Later on, 
Gopalsamy et al. synthesized a novel series of pro-
line sulfonamides which were found inhibitors of 
hepatitis C virus NS5b polymerase. The analogues 
4 and 5 displayed good activity with IC50 values of 
0.08 and 0.26 µM respectively51 (Fig. 3). A series of 
tetra-and tripeptide based acyl sulfonamides were 
synthesized and screened against hepatitis C virus 
(HCV) NS3 protease. Ronn and colleagues observed 
that the compound 6 and 7 showed good activity 
with EC50 values of 0.040 and 4.6 µM respectively52. 
Several thiazolone-based sulfonamides as inhibitors 
of NS5B polymerase to target HCV were synthesized 
by Ding and co-workers. The derivatives 8, 9, 10 and 
11 exhibited the most potent antiviral activity with 











































































































































Fig. 3. Potent sulfonamide scaffolds having 
anti-HCV potential.
Bogen et al. executed the synthesis of novel sulfon-
amides which were found inhibitors of HCV NS3 
serine protease. The compound 12 and 13 showed 
highest potential with EC90 values of 75 and 55 nM 
respectively54. Synthesis of indole acylsulfonamides 
was executed by Anilkumar and co-workers and 
among them the compounds 14-16 displayed sig-
nificant activity against HCV (NS5B) polymerase 
with IC50 values of 0.018, 0.033 and 0.039 µM re-
spectively55. A novel library of N-phenylbenzene sul-
fonamides was prepared and evaluated as inhibitors 
of polymerase (NS5B) in hepatitis C virus by May 
and co-researchers. Compounds 17 and 18 demon-
strated good activity with IC50 values of 0.04 and 
0.9 µM respectively56 (Fig. 4). N-(4’-(Indol-2-yl)phe-
nyl) sulfonamides synthesized by Chen et al. were 
found inhibitors of HCV replication. Compound 19 
displayed best activity with EC50 value of 0.17 µM57. 
In 2013, Zhang and colleagues prepared a series of 
6-(indol-2-yl) pyridine-3-sulfonamides which were 
found inhibitors of hepatitis C virus (HCV) for the 
targeting of NS4B. Among these, derivatives 20-22 
showed similar potential with EC50 value of 2 nM58 
(Fig 4). 

















































































































































































































































































































































Fig. 5. Sulfonamide derivatives with anti-HCV potential.
A novel series of 6-(indol-2-yl) pyridine-3-sulfon-
amides, reported by Zhang et al., was found as an-
ti-HCV (NS4B). Among the reported series, the com-
pounds 23-28 displayed good activity with IC50 values 
of 2, 3, 3, 2, 4 and 4 nM respectively59 (Fig. 5). Novel 
2-phenylindole analogues as HCV replicon inhibitors 
were synthesized by Chen and co-workers. The com-
pounds 29-32 were found the most potent ones with 
IC50 values of 0.47, 0.17, 0.10 and 0.075 µM respec-
tively60. In 2014, acyl sulfonamide derivatives (BMS 
605339) were synthesized and screened against NS3 
protease inhibitor for the treatment of hepatitis C vi-
rus. From the reported series the compounds 33-36 
demonstrated good activity with IC50 values of 1, 1, 5 
and 6 nM respectively61 (Fig. 5).
A variety of 6-(azaindol-2-yl)pyridine-3-sulfon-
amides, synthesized by Chen et al., were used as po-
tent and selective inhibitors of hepatitis C virus NS4B. 
The compound 37, 38 and 39 among the series, dis-
played best activity with IC50 values of 2, 13 and 15 nM 
respectively62 (Fig. 6). Acyl sulfonamides were synthe-
sized and screened for their antiviral activity against 
hepatitis C virus. Rona and colleagues observed that 
the compound 40 showed good activity with ED50 
values of 0.040 µM63. A novel series of acyclic, acyl 
and tripeptidic sulfonamides was synthesized by Sun 
and coworkers in 2016. These compounds were used 
as protease inhibitors of hepatitis C virus. The com-
pound 41 and 42 showed the best activity with IC50 















































































Fig. 6. Some valuable anti-HCV agents 
with sulfonamide functionality.
Sulfonamides as anti-HIV agents
Nagarajan and coworkers synthesized a novel series of 
benzothiazole sulfonamides as HIV-1 protease inhib-
itors. It was observed that both the derivatives 43 and 
44 exhibited similar activity with IC50 value 2 nM65. A 
novel series of benzensulfonamides was prepared and 
screened against HIV virus by Pomarnacka et al. The 
compound 45 demonstrated best antiviral activity 
with EC50 value of 28.8 µM66. Synthesis of a novel series 
of Nα-isobutyl-Nα-arylsulfonamido-(Ne-acyl)lysine, 
lysinol and analogues was executed by Stranix and 
co-workers. They observed that the compounds 46-48 
exhibited good anti-HIV activity with EC50 values of 
540, 339 and 730 nM respectively67 (Fig. 7). A novel se-
ries of sulfonamides having caffeoyl naphthalene was 
synthesized by Xu and colleagues. The derivatives 49 
and 50 showed good activity against HIV viruses with 
IC50 values of 4.5 and 7.9 µg/ml respectively68. Synthe-
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sis of lysine sulfonamide derivatives was reported by 
Stranix et al. From the prepared series the compounds 
51 and 52 showed excellent activity with EC50 values 
of 150 and 488 nM respectively against wild type HIV 





















































































































































































































Fig. 8. Structures of important anti-HIV agents. 
In 2004, Miller and colleagues reported the synthe-
sis of anti-HIV aryl sulfonamide and its analogues. 
Among them the compound 53 demonstrated good 
activity with IC50 value of 1.6 nM, in wild type 9.2 nM 
and in mutant viruses 15 nM70. In the next year, an an-
ti-HIV series of N-alkoxy-arylsulfonamide derivatives 
was synthesized by Sherrill et al. It was observed that 
compounds 54 and 55 displayed good activity with IC50 
values of 6 and 3 nM respectively71. Oximinoarylsul-
fonamides were prepared and tested against HIV viral 
infections by Yeung and colleagues. They identified that 
the compounds 56 and 57 exhibited potent activity 
with IC50 values of 0.005 and 0.016 µM respectively72 
(Fig. 8). Later on, aryl sulfonamides were prepared by 
Miller and co-workers and tested against HIV protease 
in wild type and protease inhibitor resistant viruses. The 
compound 58 displayed good activity with IC50 value of 
0.7 nM for wild type and 0.22 nM73. Among the lysine 
containing antiviral sulfonamides, reported by Stranix 
and colleagues, the derivatives 59 and 60 demonstrated 
excellent inhibition against HIV protease cells with IC50 
values of 0.5 and 0.12 nM respectively74 (Fig. 8).  
In 2007, potent anti-HIV sulfonamide analogs were 
synthesized by Lu and co-workers. The compound 
61 and 62 displayed best activity with IC50 values of 
7 and 27 nM respectively75. In the same year, Rav-
ichandran et al. reported a novel series of aryl sul-
fonamides which exhibited anti-HIV activity. The 
best activity was showed by compound 63 and 64 
with IC50 values of 2.6 and 2.8 nM respectively76. 
A series of N-(3-amino-3,4-dihydro-4-oxopyrimi-
din-2-yl)-4-chloro-2-mercapto-5-methylbenzenesul-
fonamide derivatives were synthesized by Brzozowski 
and colleagues and tested against HIV-1 virus. The 
compound 65 and 66 exhibited good activity with 
EC50 value of 15 and 29.6 μM respectively77 (Fig. 9). 
Zareef et al. prepared novel oxadiazole based sulfon-
amides and screened them as anti-HIV-1 (strain IIIB) 
and HIV-2 (strain ROD) in human T-lymphocyte 
(MT-4) cells. The compound 67 was found the most 
potent among all the derivatives against the replica-
tion of HIV-1 and HIV-2 in cell culture with an IC50 
value of 19.5 μg/ml and a CC50 value of 55.8 μg/ml 
against HIV-178. A novel series of isoxazolidine and 
isoxazole sulfonamides was reported by Low et al. as 
inhibitors of HIV-1 replication. The compound 68-70 
displayed best activity with IC50 values of 76, 75 and 
93 μM respectively79. 6,7-Dihydroxy-1-oxoisoindo-
line-4-sulfonamides were synthesized by Zhao and 
colleagues and they observed that derivatives 71 and 
72 exhibited good activity with IC50 values of 0.047 
and 0.054 µM respectively against HIV virus80. Kim 
and co-researchers executed the synthesis of sulfon-
amides, the derivative 73 showed activity similar to 
the reference drugs (nevirapine, Azt and saquinavir) 





































































































































Fig. 9. Sulfonamide derivatives with anti-HIV potential.
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Sulfonamides as anti-Influenza, anti-dengue 
and anti-Coxacki agents
A series of benzenesulfonamide derivatives were 
reported by Tang and co-researchers which prohib-
ited cytopathic effects (CPE) caused by infection of 
influenza (A/Weiss/43 strain (H1N1)). The derivatives 
74 and 75 showed good activity with EC50 values of 
86 and 86 nM respectively82. Recently, chiral sulfon-
amides and derivatives (anti-influenza agents) were 
synthesized by Basaran and colleagues. From the 
prepared series compound 76 and 77 exhibited good 
antiviral activity with EC50 values of 1.6 and 1.7 µM 
respectively83 (Fig. 10). 
Sulfonamides as anti-dengue and anti-Coxac-
ki agents
Synthesis of 4-(1,3-dioxo-2,3-dihydro-1H-isoin-
dol-2-yl)benzene-1-sulfonamide and derivatives were 
reported by Timiri et al. These sulfonamide deriva-
tives were found to be active against dengue virus. 
The compound 78 and 79 showed good activity with 
IC50 values of 48.2 and 121.9 µM84. Synthesis of nov-
el 4-(1-aryl-2-oxo-1,2-dihydro-indol-3-ylideneami-
no)-N-substituted benzene sulfonamide derivatives 
was executed by Kumar and coworkers. These deriv-
atives were evaluated for their in vitro anti-microbial, 
antiviral and cytotoxic activities. The derivative 80 and 
81 showed moderate activity against Coxacki virus at 
45 ug/ml in both (vero and helta) cell cultures85 (Fig. 10). 
Sulfonamides as anti-HBV and anti-TMV agents
Synthesis of di-substituted sulfonamides was re-
ported by Cai and colleagues which were screened 
against hepatitis B virus infection. The compound 
82 displayed excellent activity with EC50 value of 4.55 
µM86. Synthesis of 1,3,4-thiadiazole sulfonamides was 
reported by Chen and colleagues in 2010. Screening 
against TMV showed that the compound 83 and 84 
demonstrated good anti-tobacco mosaic virus (TMV) 
activity with the inhibition of 42.0% and 42.49% re-







































































































Fig. 10. Structures of some antiviral
 sulfonamide molecules.
CONCLUSION
Viral infections have been an extreme threat to hu-
man and animal life on this globe. Currently, a signif-
icant portion of human population is suffering from 
varius viruses like HCV, HBV, HIV etc and are passing 
their lives in miserable conditions. The development 
of drug resistance strains is an alarming situation 
which requires a continued need for the development 
of new drugs with promising activities. In this work, 
we have focused on antiviral ability of various sulfon-
amide derivatives based on heterocyclic templates es-
pecially. We have shown that the modification in the 
structure of anti-viral sulfonamide drugs have also 
resulted in their increased activity. We hope that this 
elegant presentation will lead the researchers to de-
velop more effective antiviral agents in future.
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